Pay in 4 interest-free payments of $5.78 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
Medical science has made such tremendous progress that there is hardly a healthy human left. Aldous Huxley GLP-1 Agonists at a Glance First-Generation (Short-Acting) Exenatide Byetta Lixisenatide Adlyxin / Lyxumia Second-Generation (Long-Acting) Exenatide ER Bydureon (weekly, now discontinued in some markets) Liraglutide Victoza (diabetes), Saxenda (obesity) Dulaglutide Trulicity Semaglutide Ozempic (diabetes), Wegovy (obesity), Rybelsus (oral) Dual Agonist (GIP + GLP-1) Tirzepatide Mounjaro (diabetes), Zepbound (obesity) Triple or Combination Agonists (In Development) Retatrutide Triple agonist (GLP-1 + GIP + glucagon) CagriSema Combination of cagrilintide + semaglutide (GLP-1 + amylin analog) Orforglipron Oral, non-peptide GLP-1 receptor agonist (Eli Lilly) Danuglipron Oral small-molecule GLP-1 agonist (Pfizer) Efinopegdutide GLP-1/glucagon dual agonist (Merck/Biocon) AMG133 GLP-1 + GIP receptor modulator (Amgen)
When someone takes a GLP-1 agonist such as Ozempic or Wegovy, the drug activates the same receptors as the natural hormone, leading to better blood sugar control, reduced appetite, and weight loss
Several clinical studies have found that GSH consumption exists in the blood of patients with myocardial infarction and the left ventricle of patients with heart failure [8, 38, 39]
At BHRC, we offer pharmaceutical-grade peptides administered under physician supervision
doi: 10.1016/j.bbagen.2012.09.008 7
